{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05036252",
            "orgStudyIdInfo": {
                "id": "21-271"
            },
            "organization": {
                "fullName": "Memorial Sloan Kettering Cancer Center",
                "class": "OTHER"
            },
            "briefTitle": "Study of Cardiopulmonary Exercise Testing in Women Who Have HER2-Positive Breast Cancer With Mild Cardiotoxicity",
            "officialTitle": "A Pilot Study of Cardiopulmonary Exercise Testing in Patients With Left Ventricular Systolic Dysfunction Receiving HER2-Targeted Therapy",
            "therapeuticArea": [
                "Oncology and Hematology",
                "Other"
            ],
            "study": "study-of-cardiopulmonary-exercise-testing-in-women-who-have-positive-breast-cancer-with-mild-cardiotoxicity"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-09",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2021-08-27",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-08-27",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-08-27",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2021-08-30",
            "studyFirstSubmitQcDate": "2021-08-30",
            "studyFirstPostDateStruct": {
                "date": "2021-09-05",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-09-14",
            "lastUpdatePostDateStruct": {
                "date": "2023-09-15",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Memorial Sloan Kettering Cancer Center",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "isFdaRegulatedDrug": false,
            "isFdaRegulatedDevice": true
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this study is to find out how much oxygen is used during a cardiopulmonary exercise test (CPET) in women who have mild cardiotoxicity after standard treatment for HER2-positive breast cancer, and to see whether the results of this test can be used to predict how well participants' heart and lungs will work if they continue to receive this kind of treatment."
        },
        "conditionsModule": {
            "conditions": [
                "Breast Cancer",
                "HER2-positive Breast Cancer",
                "HER2-positive Metastatic Breast Cancer",
                "Breast Cancer Stage I",
                "Breast Cancer Stage II",
                "Breast Cancer Stage III",
                "Breast Cancer Stage IV",
                "Cardiotoxicity"
            ],
            "keywords": [
                "HER2-positive breast cancer",
                "cardiotoxicity",
                "HER2-targeted therapy",
                "Breast cancer",
                "21-271",
                "Memorial Sloan Kettering Cancer Center"
            ]
        },
        "designModule": {
            "studyType": "OBSERVATIONAL",
            "patientRegistry": false,
            "designInfo": {
                "observationalModel": "COHORT",
                "timePerspective": "PROSPECTIVE"
            },
            "enrollmentInfo": {
                "count": 30,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Participants with HER2-positive breast cancer",
                    "description": "Participants with HER2-positive breast cancer who have developed mild cardiotoxicity during HER2-targeted therapy, defined by a decline in LVEF \\> 10% to \\< 53% without symptoms of clinical heart failure (NYHA class III or IV), will be eligible for participation in this study.",
                    "interventionNames": [
                        "Diagnostic Test: Cardiopulmonary Exercise Test",
                        "Diagnostic Test: Echocardiogram",
                        "Diagnostic Test: Echocardiography"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DIAGNOSTIC_TEST",
                    "name": "Cardiopulmonary Exercise Test",
                    "description": "All enrolled participants will undergo a cardiopulmonary exercise test (CPET). The CPET will be conducted using an electronic motorized treadmill with 12-lead ECG monitoring performed by ACSM-certified exercise physiologists.",
                    "armGroupLabels": [
                        "Participants with HER2-positive breast cancer"
                    ],
                    "otherNames": [
                        "CPET"
                    ]
                },
                {
                    "type": "DIAGNOSTIC_TEST",
                    "name": "Echocardiogram",
                    "description": "Resting assessment of LVEF and GLS will be evaluated through Conventional 2D and Doppler echocardiograms will be performed per protocol using a commercially available ultrasound scanner, according to the American Society of Echocardiography (ASE) recommendations for a comprehensive examination.",
                    "armGroupLabels": [
                        "Participants with HER2-positive breast cancer"
                    ]
                },
                {
                    "type": "DIAGNOSTIC_TEST",
                    "name": "Echocardiography",
                    "description": "As soon as possible following completion of the CPET, subjects will be placed in the supine position and 2D echocardiographic images will be obtained in the apical 4-/ 3-/2-chamber views.",
                    "armGroupLabels": [
                        "Participants with HER2-positive breast cancer"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Baseline VO2peak in participants with HER2-positive breast cancer",
                    "description": "The primary purpose is to evaluate baseline VO2peak in patients with HER2-positive solid tumors and left ventricular systolic dysfunction",
                    "timeFrame": "At baseline"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Age \u2265 18 years\n* Female\n* Diagnosed with a HER2-positive solid tumor (stage I-IV)\n* Left ventricular dysfunction prior to the start of HER2-targeted therapy, defined by a LVEF \\< 53% (or lower limit of normal), or diagnosed with mild cardiotoxicity associated with HER2-targeted therapy, defined by an absolute decrease in LVEF \u2265 10% from pre-treatment to \\< 53%\n* Planning to undergo treatment with HER2-targeted therapy (e.g. trastuzumab, pertuzumab, or ado-trastuzumab) for a minimum of 3 months (i.e. 4 cycles administered every 3 weeks).\n* Willing and able to comply with the requirements of the protocol\n\nExclusion Criteria:\n\n* Symptomatic heart failure (New York Heart Association Class III or IV)\n* Subjects must not have any of the following absolute contraindications to cardiopulmonary exercise testing:\n\n  * Acute myocardial infarction (within 30 days of any planned study procedures),\n  * Unstable angina\n  * Uncontrolled arrhythmias causing symptoms or hemodynamic compromise,\n  * Symptomatic severe aortic stenosis\n  * Recurrent syncope\n  * Active endocarditis\n  * Acute myocarditis or pericarditis\n  * Acute pulmonary embolus or pulmonary infarction (within 3 months of any planned study procedures)\n  * Thrombosis of lower extremities (within 3 months of any planned study procedures)\n  * Suspected dissecting aneurysm\n  * Uncontrolled asthma\n  * Pulmonary edema\n  * Room air desaturation at rest \u2264 85%\n  * Respiratory failure\n  * Acute noncardiopulmonary disorder that may affect exercise performance or be aggravated by exercise (i.e., infection, renal failure, thyrotoxicosis)\n  * Mental impairment leading to inability to cooperate.\n* Enrollment onto any other interventional investigational study\n* Inability to provide informed consent",
            "healthyVolunteers": false,
            "sex": "FEMALE",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ],
            "studyPopulation": "Potential research participants will be identified by a member of the participant's treatment team, the protocol investigator, or research team at Memorial Sloan Kettering Cancer Center (MSK). If the investigator is a member of the treatment team, s/he will screen their potential participant's medical records for suitable research study participants and discuss with the subject their potential for enrolling in the research study.",
            "samplingMethod": "NON_PROBABILITY_SAMPLE"
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Anthony Yu, MD",
                    "role": "CONTACT",
                    "phone": "212-639-7932",
                    "email": "yua3@mskcc.org"
                },
                {
                    "name": "Jennifer Liu, MD",
                    "role": "CONTACT",
                    "phone": "212-639-8220",
                    "email": "liuj1234@mskcc.org"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Anthony Yu, MD",
                    "affiliation": "Memorial Sloan Kettering Cancer Center",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Memorial Sloan - Kettering Cancer Center",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10021",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Anthony Yu, MD",
                            "role": "CONTACT",
                            "phone": "212-639-7932"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "Memorial Sloan Kettering Cancer Center",
                    "url": "http://www.mskcc.org"
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org."
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000001943",
                    "term": "Breast Neoplasms"
                },
                {
                    "id": "D000066126",
                    "term": "Cardiotoxicity"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000001941",
                    "term": "Breast Diseases"
                },
                {
                    "id": "D000012871",
                    "term": "Skin Diseases"
                },
                {
                    "id": "D000006331",
                    "term": "Heart Diseases"
                },
                {
                    "id": "D000002318",
                    "term": "Cardiovascular Diseases"
                },
                {
                    "id": "D000010335",
                    "term": "Pathologic Processes"
                },
                {
                    "id": "D000064420",
                    "term": "Drug-Related Side Effects and Adverse Reactions"
                },
                {
                    "id": "D000064419",
                    "term": "Chemically-Induced Disorders"
                },
                {
                    "id": "D000011832",
                    "term": "Radiation Injuries"
                },
                {
                    "id": "D000014947",
                    "term": "Wounds and Injuries"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5220",
                    "name": "Breast Neoplasms",
                    "asFound": "Breast Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M30670",
                    "name": "Cardiotoxicity",
                    "asFound": "Cardiotoxicity",
                    "relevance": "HIGH"
                },
                {
                    "id": "M27583",
                    "name": "Systolic Murmurs",
                    "relevance": "LOW"
                },
                {
                    "id": "M5218",
                    "name": "Breast Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M15674",
                    "name": "Skin Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M9419",
                    "name": "Heart Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M30303",
                    "name": "Drug-Related Side Effects and Adverse Reactions",
                    "relevance": "LOW"
                },
                {
                    "id": "M30302",
                    "name": "Chemically-Induced Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M14679",
                    "name": "Radiation Injuries",
                    "relevance": "LOW"
                },
                {
                    "id": "M17685",
                    "name": "Wounds and Injuries",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC14",
                    "name": "Heart and Blood Diseases"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "BC25",
                    "name": "Substance Related Disorders"
                },
                {
                    "abbrev": "BC26",
                    "name": "Wounds and Injuries"
                }
            ]
        }
    },
    "hasResults": false
}